95656-86-3

Usage

Uses

Used in Organic Synthesis:
1-(BOC-AMINO)-2-PROPANOL is used as a building block for the synthesis of various organic compounds, providing a protected amino group that can be selectively deprotected when needed. This feature is crucial for the synthesis of complex organic molecules with specific functional groups.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 1-(BOC-AMINO)-2-PROPANOL is used as a reagent in the production of drugs. Its ability to protect the amino group simplifies the synthesis process, allowing for the creation of pharmaceutical compounds with greater ease and precision.
Used in Agrochemicals:
1-(BOC-AMINO)-2-PROPANOL also finds application in the agrochemical sector, where it is used in the synthesis of various agrochemical products. Its protective group facilitates the synthesis of complex molecules with specific biological activities, contributing to the development of effective crop protection agents.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
1-(BOC-AMINO)-2-PROPANOL is utilized as a chiral auxiliary in asymmetric synthesis, playing a critical role in the production of enantiomerically pure compounds. This application is particularly important in the synthesis of chiral pharmaceuticals, where the stereochemistry of the molecule can significantly impact its biological activity and efficacy.

InChI:InChI=1/C8H17NO3/c1-6(10)5-9-7(11)12-8(2,3)4/h6,10H,5H2,1-4H3,(H,9,11)

Upstream product

• 2592-18-9 tert-Butoxycarbonylamino-3-hydroxy-butyric acid 
• 34619-03-9 tert-butyldicarbonate 
• 78-96-6 3-amino-2-propanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 147252-81-1 acetone O-(tert-butoxycarbonyl)oxime 

Downstream Products

• 129319-71-7 (+/-)-N-(tert-Butoxycarbonyl)-2-methylaziridine 
• 1308799-02-1 (+)-(2S)-tert-butyl 2-(4-methoxybenzyl)-4-methyl-4-[(trimethylsilyl)oxy]pyrrolidine-1-carboxylate 
• 1308799-10-1 (+)-(2S)-tert-butyl 4-hydroxy-2-(4-methoxybenzyl)-4-methylpyrrolidine-1-carboxylate 
• 1318907-32-2 (±)-N-methyl-N-methoxy-2-{[1-(tert-butoxycarbonylamino)prop-2-yl]oxy}benzamide 
• 1332758-52-7 tert-butyl 2-(5-fluoro-2-(5-methyl-6-(methylcarbamoyl)thieno[2,3-d]pyrimidin-4-ylamino)phenoxy)propyl carbamate 
• 1332758-51-6 4-(2-(1-(tert-butoxycarbonylamino)propan-2-yloxy)-4-fluorophenylamino)-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylic acid 
• 1332758-69-6 tert-Butyl 2-(2-(6-carbamoyl-5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)-5-fluorophenoxy)propylcarbamate 
• 1332758-50-5 methyl 4-(2-(1-(tert-butoxycarbonylamino)propan-2-yloxy)-4-fluorophenylamino)-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylate 
• 1332758-71-0 (R)-tert-butyl 2-(2-(6-carbamoyl-5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)-5-fluorophenoxy)propylcarbamate 
• 1332758-70-9 (S)-tert-butyl 2-(2-(6-carbamoyl-5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)-5-fluorophenoxy)propylcarbamate 
• 1297543-17-9 (S)-4-(1-(1-Aminopropan-2-yl)-1H-pyrazol-3-yl)-2-chloro-6-fluoro-benzonitrile 
• 1403334-65-5 (R)-4-(1-(1-aminopropan-2-yl)-1H-pyrazol-3-yl)-2-chloro-6-fluoro-benzonitrile 
• 119768-44-4 tert-butyl [(2R)-2-hydroxypropyl]carbamate 
• 167938-56-9 tert-butyl [(2S)-2-hydroxypropyl]carbamate 

Relevant academic research and scientific papers

Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds

Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.

Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells

The enzymes involved in the metabolic pathways in cancer cells have been demonstrated as important therapeutic targets such as the isocitrate dehydrogenase 2 (IDH2). A series of macrocyclic derivatives was designed based on the marketed IDH2 inhibitor AG-221 by using the conformational restriction strategy. The resulted compounds showed moderate to good inhibitory potential against different IDH2-mutant enzymes. Amongst, compound C6 exhibited better IDH2R140Q inhibitory potency than AG-221, and showed excellent activity of 2-hydroxyglutarate (2-HG) suppression in vitro and its mesylate displayed good pharmacokinetic profiles. Moreover, C6 performed strong binding mode to IDH2R140Q after computational docking and dynamic simulation, which may serve as a good starting point for further development.

QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

NON-FUSED TRICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS

The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates.

NOVEL CONDENSED PYRAZOLE DERIVATIVE AND MEDICAL USES THEREOF

PROBLEM TO BE SOLVED: To provide a preventive or therapeutic agent for mood disorder, anxiety disorder, schizophrenia, dementia, drug dependence or the like related to subtypes of metabolism type glutamate receptor (mGlu) 2 and 3. SOLUTION: There are prov

CHEMICAL BLOWING AGENT AND THERMALLY EXPANDABLE THERMOPLASTIC COMPOSITION

The present invention relates to a chemical blowing agent comprising at least one tertiary alkyl carbamate. The chemical blowing agent can be activated thermally and is suitable for foaming thermoplastic materials and can for example be incorporated into thermally expandable baffle and/or reinforcement elements which are used in automotive manufacturing and building insulation.